Polyomavirus nephropathy in kidney transplantation

Jennifer Trofe*, Jennifer Gordon, Prabir Roy-Chaudhury, Igor J. Koralnik, Walter J. Atwood, Rita R. Alloway, Kamel Khalili, E. Steve Woodle

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Polyomavirus nephropathy has become an important complication in kidney transplantation, with a prevalence of 1% to 8%. Unfortunately, the risk factors for polyomavirus nephropathy and renal allograft loss are not well defined. The definitive diagnosis is made through assessment of a kidney transplant biopsy. Recently, noninvasive urine and serum markers have been used to assist in polyomavirus nephropathy diagnosis and monitoring. Primary treatment is immunosuppression reduction, but must be balanced with the risks of rejection. No antiviral treatments for polyomavirus nephropathy have been approved by the Food and Drug Administration. Although cidofovir has shown in vitro activity against murine polyomaviruses, and has been effective in some patients, it is associated with significant nephrotoxicity. Graft loss due to polyomavirus nephropathy should not be a contraindication to retransplantation; however, experience is limited. This review presents potential risk factors, screening, diagnostic and monitoring methods, therapeutic management, and retransplantation experience for polyomavirus nephropathy.

Original languageEnglish (US)
Pages (from-to)130-142
Number of pages13
JournalProgress in Transplantation
Issue number2
StatePublished - Jun 1 2004

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Polyomavirus nephropathy in kidney transplantation'. Together they form a unique fingerprint.

Cite this